Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of osteoporosis and rheumatic diseases such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis and other related musculoskeletal diseases. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in rheumatology, osteoporosis and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be follows (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; online publication is usually within 3 weeks of Acceptance.
